Table 1.
Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening
| Marker | Implication of mutation | Diagnosis |
| EGF/EGFR | Constitutive activation of mitogen-activated protein kinase pathway | Screening for the patients more likely to respond to EGFR inhibitors |
| TGF-A | Promotes metastasis | |
| Brings about epithelial mesenchymal transition | ||
| VEGF/VEGFR | Tumor cell invasion and migration promoting tumor progression | Good diagnostic tool especially in combination with Cx43 |
| Lymphangiogenesis and lymphatic metastasis | ||
| FGF | Cell proliferation, migration, and invasion | Serum FGF-BP1 can be used as a marker for high-risk premalignant lesions |
| MMPs | Digestion of extracellular components | MMP-2 in pancreatic juice |
| Cell dissociation and subsequent invasion | Serum MMP-9 | |
| Plasma MMP-7 levels help to distinguish between PC and CP | ||
| miRNAs | Invasive capacity | Plasma miRNA profiling for blood-based biomarkers |
| Metastasis and maintenance of cancer |
EGF: Endothelial growth factor; EGFR: Endothelial growth factor together with its receptors; TGF-A: Tumor growth factor-A; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor and its receptor; FGF: Fibroblast growth factor; MMPs: Metalloproteinases; PC: Pancreatic carcinoma; CP: Chronic pancreatitis.